Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q3 2025 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen, and welcome to the Verrica Pharmaceuticals' Third Quarter 2025 Corporate Update Conference Call.
Verrica Pharmaceuticals Inc. (VRCA)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Armistice Capital Steven Boyd | 1,118,925 | $9,298,267 | +76% | 0.11% |
| 2. | Caligan Partners David Johnson | 923,910 | $7,677,692 | 0.63% | |
| 3. | Velan Capital Adam Morgan | 471,559 | $3,918,655 | 2.27% | |
| 4. | Stonepine Capital Timothy P. Lynch | 353,669 | $2,938,989 | 2.15% | |
| 5. | Kalehua Capital Management Tai-Li Chang | 235,779 | $1,959,323 | 1.94% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.24 | 2,357 | $9,999.57 | 2,357 | 2025-11-25 | Filing | |
| $4.24 | 3,536 | $15,001.48 | 8,962 | 2025-11-25 | Filing | |
| $4.24 | 10,000 | $42,425.00 | 21,000 | 2025-11-25 | Filing | |
| $4.24 | 94,311 | $400,114.42 | 182,593 | 2025-11-25 | Filing | |
| $4.24 | 2,750,762 | $11,670,107.79 | 3,348,372 | 2025-11-25 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.65 | 4,315 | $2,804.75 | 176,458 | 2025-03-17 | Filing | |
| $2.46 | 9,530 | $23,443.80 | 105,773 | 2024-08-27 | Filing | |
| $2.66 | 26,183 | $69,646.78 | 115,303 | 2024-08-26 | Filing | |
| $2.46 | 3,601 | $8,858.46 | 94,261 | 2024-08-27 | Filing | |
| $2.66 | 9,888 | $26,302.08 | 97,862 | 2024-08-26 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 707,338 | $5,877,979 | 0.33% | |
| 2. | 280,734 | $2,332,900 | 0.03% | |
| 3. | 138,194 | $1,148,392 | 0% | |
| 4. | 118,218 | $982,392 | 0% | |
| 5. | 101,722 | $845,310 | 0% |
News See All
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q2 2025 Earnings Call Transcript
Operator: Good evening, ladies and gentlemen, and welcome to the Verrica Pharmaceuticals Second Quarter 2025 Corporate Update Conference Call.
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q4 2024 Earnings Call Transcript
Operator: Good evening, ladies and gentlemen, and welcome to the Verrica Pharmaceuticals’ Fourth Quarter and Full Year 2024 Corporate Update Conference Call.
15 Worst 52-Week Low Stocks to Buy Now According to Short Sellers
The U.S. Federal Reserve conducting a 50 basis point interest rate cut was the catalyst that stocks needed to bounce back from a period of stagnation.
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q2 2024 Earnings Call Transcript
Operator: Good morning, and welcome to the Verrica Pharmaceuticals Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q1 2024 Earnings Call Transcript
Operator: Ladies and gentlemen, good morning, and welcome to the Verrica Pharmaceuticals First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q4 2023 Earnings Call Transcript
Verrica Pharmaceuticals Inc. misses on earnings expectations. Reported EPS is $-0.53 EPS, expectations were $-0.47. Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q3 2023 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen, and welcome to the Verrica Pharmaceuticals Third Quarter 2023 Corporate Update and Earnings Conference Call.
Hedge Fund and Insider Trading News: Paul Marshall, Crispin Odey, Point72 Asset Management, Asgard Fixed Income Fund, Brookfield Hedge Solutions Advisors, B Riley Financial Inc (RILY), Verrica Pharmaceuticals Inc. (VRCA), and More
GB News owner Sir Paul Marshall’s hedge fund has made a multi-million pound gain on its bet against NatWest shares following the exit of Dame Alison Rose.
12 Most Promising Micro-Cap Stocks According to Analysts
In this article, we will take a look at the 12 most promising micro-cap stocks according to analysts.
Hedge Fund Resource Center